Biocon is declaring its April-June quarter performance on Thursday. Analysts expect consolidated net profit to grow 27-32 per cent year-on-year to ₹110-135 crore. Consolidated revenue is seen growing 20 per cent at ₹830 crore. The management had indicated in the annual report a greater investment in R&D, enhance operating efficiencies with a focus on product launches and licensing opportunities. Developments on those front will remain in focus.
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.